Business
Quarterly Activities Report for June 2022
ADELAIDE, Australia, July 29, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a global, clinical stage
About this update from Neuphoria Therapeutics Inc.
[{"type":"text","content":"ADELAIDE, Australia, July 29, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a global, clinical stage biopharmaceutical company, today released its Quarterly Activities and ASX Appendix 4C Cashflow Reports. Highlights during the Quarter ended 30 June 2022 (Quarter) and up to the date of this announcement include: On 6 April 2022, Bionomics’ Executive Chairman, Dr. Errol De Souza, participated in a Fireside Chat hosted by Berenberg Capital Markets analyst Esther Hong to discuss the ongoing BNC210 Phase 2 Social Anxiety Disorder (SAD) PREVAIL, and Post-Traumatic Stress Disorder (PTSD) ATTUNE, trials.On 29 April 2022, Bionomics released its Appendix 4C – Quarterly Cashflow Report for the quarter ended 31 March 2022.On 16 May 2022, Bionomics announced that it would be participating in three upcoming investor conferences including: Citibank Biotech’s Mood Disorders/Mental Health Panel, 18 May 2022Berenberg Capital Markets’ Emerging Biotech Conference, 19 May 2022H.C. Wainwright’s Global Investment Conference, 24-27 May 2022. On 15 June 2022, Bionomics held a virtual investor webinar with Executive Chairman Dr. Errol De Souza and Vice President of Strategy and Corporate Development Mr. Connor Bernstein. The presentation covered Bionomics’ ongoing Phase 2 trials for SAD and PTSD and the pressing need for new treatments for patients suffering from these disorders. The presenters also discussed the Company’s near-term milestones and goals for 2022 and beyond.The Company’s cash balance on 30 June 2022 was $33.56 million (31 March 2021: $39.58 million).Payments for research & development expenditure during the Quarter increased to $4.18 million from $2.27 million compared with the previous Quarter, that is, an increase of 84.14%, primarily associated with the ATTUNE and PREVAIL Studies. The ATTUNE Study is evaluating the oral tablet formulation of BNC210 compared to placebo in approximately 200 PTSD patients in the U.S. There are 25 clinical sites open and recruitment of trial participants is underway. The PREVAIL Study is evaluating two doses of the oral tablet formulation of BNC210 compared to placebo as an acute treatment for SAD in approximately 150 patients in the U.S. There are 14 clinical sites open and recruitment of trial participants is underway. For the purpose of ASX Listing Rule 4....